Atreca has announced it has secured $56 million in series A funding.
Atreca, based in Redwood City, California, is a privately held biotechnology company developing therapeutics drawn from human immune responses, including anti-cancer immune responses.
The funding round was led by an unidentified “large, U.S.-based, healthcare-focused fund.” Additional investors included the Bill & Melinda Gates Foundation, Mission Bay Capital and GlaxoSmithKline.
Atreca indicated it will use the financing to further development and advancement of the company’s product pipeline.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
